Pentavalent DTaP-Hep B-IPV
Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix™; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Torrance, California, United States, 90502
- UCLA Center for Vaccine Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Prenatal Inclusion Criteria
- Generally healthy, pregnant mother
- Mother will deliver at a Kaiser Permanente Medical Center participating in the study
- Ability of the parent(s) to understand and comply with the requirements of the protocol
- Signed informed consent by parent(s)
Birth Inclusion Criteria
- Healthy newborn 0 to 5 days of age
- Gestational age greater than or equal to 37 weeks to less than or equal to 42 weeks and birth weight greater than 2500 grams
- Signed informed consent obtained
- Mother continues to be eligible by prenatal screening criteria
- Newborn will receive future well child care at a Kaiser Permanente study clinic
- After reviewing with parent(s) the study procedures and informed consent, parent wishes to continue in the study
Exclusion Criteria:
Prenatal Exclusion Criteria
- Mother positive for hepatitis B surface antigen (HBsAg) or whose antigen status is unknown
- Mother positive for human immunodeficiency virus (HIV) or whose antigen status is unknown
- Mother positive for rapid plasma reagin (RPR) (syphilis) or whose antigen status is unknown
- Mother or immediate family member has impaired immunologic function
- Mother is expected to take immune suppressant medications during the last trimester of pregnancy
- Mother is expected to receive blood, blood products or immunoglobulin preparation (including hepatitis B immune globulin [HBIG]) during the last trimester of the pregnancy
- Mother with insulin dependent diabetes
- Mother with pre-eclampsia, eclampsia or abruptio placentae
- Pregnancy associated with known congenital defects
- Mother participating in another study with a non-Food and Drug Administration (FDA) approved drug, vaccine or device
- Parent(s)/guardian cannot be contacted by telephone
- Parent(s)/guardian will not continue well child care at a Kaiser Permanente study clinic
- Mother who is requesting that cord blood be retained for stem cell preservation
- Other maternal conditions that, in the opinion of the investigator, would interfere with the study
Birth Exclusion Criteria
- Current receipt of antibiotics for suspected infection in mother or newborn (based on presence of maternal fever greater than or equal to 38.0 degrees Celsius or prolonged rupture of membranes greater than or equal to 18 hours)
- Rectal temperature greater than or equal to 38.0 degrees Celsius
- Newborn receiving resuscitation [including intubation, mechanical ventilation or intravenous (IV) medication] at birth
- Suspected medical, congenital, developmental or surgical disease, including immunodeficiency, neurology disorder or seizure disorder, severe congenital anomalies or multi-organ dysfunction
- Prior receipt of hepatitis B vaccine or any other vaccine
- Received or plans to receive any immunosuppressant medication
- Receipt of blood products or immunoglobulin [including Hepatitis B Immune Globulin (HBIG)]
- Clinically significant findings on review of medical history and physical exam determined by the investigator or sub-investigator to be sufficient for exclusion
- Mother of newborn with insulin dependent diabetes
- Mother of newborn with pre-eclampsia, eclampsia or abruptio placentae
- Mother of newborn positive for HBsAG, HIV or RPR (syphilis) or whose antigen status is unknown
- Impaired immunologic function in newborn or family member
- Any condition determined by the investigator that would interfere with the evaluation of the vaccine or be a potential health risk to the subject
- Newborn is participating in another research study or has received a non-FDA approved drug or vaccine (excluding formula preparations) prior to study entry
- Parent(s)/guardian who are unable to be contacted by telephone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group A
Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
|
U.S. licensed 13-Dec-2002.
Dosage equal to 0.5 mL administered intramuscularly.
Combination vaccine.
Commercially prepared normal saline.
The dose will be 0.5 mL administered intramuscularly.
|
|
Active Comparator: Group B
Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
|
U.S. licensed 13-Dec-2002.
Dosage equal to 0.5 mL administered intramuscularly.
Combination vaccine.
U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide.
The vaccine is given to infants as a 0.5 mL dose intramuscularly.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess the immune responses to each vaccine antigen over time, antibodies to pertussis (PT, FHA, PRN), diphtheria, tetanus, Hib, polio (Types 1, 2, 3) and hepatitis B (HbsAg) will be evaluated.
Time Frame: Day 0-5, Day 53-70, Day 113-130, Day 173-190, and Visit 4 + (28-42 days).
|
Day 0-5, Day 53-70, Day 113-130, Day 173-190, and Visit 4 + (28-42 days).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess vaccine safety, systemic and local immediate reactions.
Time Frame: 30 mins after each immunization; 7 days following each vaccination; contacted 2-3 and 8 days following each vaccination to collect AE information; SAEs will be collected throughout study participation.
|
30 mins after each immunization; 7 days following each vaccination; contacted 2-3 and 8 days following each vaccination to collect AE information; SAEs will be collected throughout study participation.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Neuromuscular Diseases
- Central Nervous System Infections
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Enterovirus Infections
- Picornaviridae Infections
- Spinal Cord Diseases
- Corynebacterium Infections
- Hepatitis
- Myelitis
- Hepatitis B
- Diphtheria
- Poliomyelitis
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
Other Study ID Numbers
- 03-062
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.